Vertex Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell VRTX and other ETFs, options, and stocks.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
VRTX News
CRISPR Therapeutics CRSP reported earnings of $1.43 per share in the first quarter of 2024, surpassing the Zacks Consensus Estimate of a loss of $1.63. In the y...
Key Insights Vertex Pharmaceuticals to hold its Annual General Meeting on 15th of May CEO Reshma Kewalramani's total compensation includes salary of US$1.50m...
As you might know, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) just kicked off its latest quarterly results with some very strong numbers. Vertex Pharmace...
Analyst ratings
62%
of 34 ratingsMore VRTX News
Vertex Pharmaceuticals Inc. (VRTX) has disclosed a new risk, in the Corporate Activity and Growth category. Vertex Pharmaceuticals Inc. faces significant risk...
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) showcases robust revenue growth and solid operational performance in its latest 10-Q filing. Strategic acquisitions an...
CRISPR Therapeutics AG -More than 25 authorized treatment centers (ATCs) activated globally for CASGEVY™ and multiple patients have already had cells collected...
Loading... Loading... Financial giants have made a conspicuous bullish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceutica...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Pipeline and key...
For the quarter ended March 2024, Vertex Pharmaceuticals (VRTX) reported revenue of $2.69 billion, up 13.3% over the same period last year. EPS came in at $4.76...
Vertex Pharmaceuticals (NASDAQ:VRTX) First Quarter 2024 Results Key Financial Results Revenue: US$2.69b (up 13% from 1Q 2023). Net income: US$1.10b (up 57% f...
